Since we demonstrated the importance of targeting the p62-ZZ-GFI1 signaling axis within BMSCs to decrease (or rescue from) their response to MM cells, altogether our patient data suggests that patients with bone involvement may benefit more from XRK3F2 treatment than those without bone disease. Here, SQSTM1 is linked to Miyoshi myopathy.